Global Amifostine Market to Grow at a CAGR of 2.2% from 2017 to 2025 According to Latest Research
This report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market
(EMAILWIRE.COM, July 29, 2018 ) The Global Amifostine Market is Valued at 48 million US$ in 2017 and will reach 57 million US$ by the end of 2025, growing at a CAGR of 2.2% during 2018-2025.
Amifostine is a pro-drug which is activated to the free thiol metabolite at the tissue site. The thiol metabolite is responsible for most of the cytoprotective and radioprotective properties of amifostine. It is readily taken up by cells where it binds to and detoxifies reactive metabolites of platinum and alkylating agents as well as scavenges free radicals. Other possible effects include inhibition of apoptosis, alteration of gene expression and modification of enzyme activity. Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumour cells.
Consumption of amifostine mainly concentrates in North America. In 2016, the region consumed 780 K Unit, holding about 52% market share globally. The follower is Asia-Pacific, with about 41% consumption share.
The market is relatively concentrated and there are just a few suppliers in the market, such as Clinigen Group, Sun Pharmaceutical, Merro Pharmaceutical and so on. Clinigen Group acquired the business from AstraZeneca in the year of 2014 and signed an agreement with Cumberland in the year of 2016. Under the agreement, Cumberland acquired the exclusive rights to commercialize Ethyol in the United States. Merro Pharmaceutical own the largest sales share in China.
Amifostine shows good effect in reducing harmful effects of cisplatin chemotherapy on kidneys in women treated for advanced ovarian cancer as well as relieving dry mouth problems (xerostomia) with head and neck cancer patients undergoing radiation treatment. It is estimated that the amifostine market will keep upward tendency and to be worthy of 49.99 million USD in 2023 globally.
Access this report at: https://www.themarketreports.com/report/global-amifostine-market-professional-survey-report-2018
Companies profiled in this report are Clinigen Group, Sun Pharmaceutical, Taj Pharmaceuticals, Merro Pharmaceutical, Luye Pharma, Mingren Pharma and more.
Analysis by Product Types, with production, revenue, price, market share and growth rate of each type, can be divided into
• 400mg/Dose
• 500mg/Dose
Analysis by Applications, this report focuses on consumption, market share and growth rate of Amifostine in each application, can be divided into
• Head and Neck Cancer Adjuvant Therapy
• Others
Purchase this premium research report at: https://www.themarketreports.com/report/buy-now/976410
Table of Contents:
1 Industry Overview of Amifostine
2 Manufacturing Cost Structure Analysis of Amifostine
3 Technical Data and Manufacturing Plants Analysis of Amifostine
4 Global Amifostine Overall Market Overview
5 Amifostine Regional Market Analysis
6 Global 2013-2018E Amifostine Segment Market Analysis (by Type)
7 Global 2013-2018E Amifostine Segment Market Analysis (by Application)
8 Major Manufacturers Analysis of Amifostine
9 Development Trend of Analysis of Amifostine Market
10 Amifostine Marketing Type Analysis
11 Consumers Analysis of Amifostine
12 Conclusion of the Global Amifostine Market Professional Survey Report 2017
Inquire more about this report at: https://www.themarketreports.com/report/ask-your-query/976410
The Market Reports
We aim to provide the best industry and market research report to a seeker. Today, ‘The Market Reports’ is a one stop destination for all the report buyers. We have a collection of over 700,000+ research, company, market, SWOT, trends and analysis reports of various countries, categories and domain to meet an organization need.
Website: https://www.themarketreports.com/
Write us at sales@themarketreports.com
Amifostine is a pro-drug which is activated to the free thiol metabolite at the tissue site. The thiol metabolite is responsible for most of the cytoprotective and radioprotective properties of amifostine. It is readily taken up by cells where it binds to and detoxifies reactive metabolites of platinum and alkylating agents as well as scavenges free radicals. Other possible effects include inhibition of apoptosis, alteration of gene expression and modification of enzyme activity. Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumour cells.
Consumption of amifostine mainly concentrates in North America. In 2016, the region consumed 780 K Unit, holding about 52% market share globally. The follower is Asia-Pacific, with about 41% consumption share.
The market is relatively concentrated and there are just a few suppliers in the market, such as Clinigen Group, Sun Pharmaceutical, Merro Pharmaceutical and so on. Clinigen Group acquired the business from AstraZeneca in the year of 2014 and signed an agreement with Cumberland in the year of 2016. Under the agreement, Cumberland acquired the exclusive rights to commercialize Ethyol in the United States. Merro Pharmaceutical own the largest sales share in China.
Amifostine shows good effect in reducing harmful effects of cisplatin chemotherapy on kidneys in women treated for advanced ovarian cancer as well as relieving dry mouth problems (xerostomia) with head and neck cancer patients undergoing radiation treatment. It is estimated that the amifostine market will keep upward tendency and to be worthy of 49.99 million USD in 2023 globally.
Access this report at: https://www.themarketreports.com/report/global-amifostine-market-professional-survey-report-2018
Companies profiled in this report are Clinigen Group, Sun Pharmaceutical, Taj Pharmaceuticals, Merro Pharmaceutical, Luye Pharma, Mingren Pharma and more.
Analysis by Product Types, with production, revenue, price, market share and growth rate of each type, can be divided into
• 400mg/Dose
• 500mg/Dose
Analysis by Applications, this report focuses on consumption, market share and growth rate of Amifostine in each application, can be divided into
• Head and Neck Cancer Adjuvant Therapy
• Others
Purchase this premium research report at: https://www.themarketreports.com/report/buy-now/976410
Table of Contents:
1 Industry Overview of Amifostine
2 Manufacturing Cost Structure Analysis of Amifostine
3 Technical Data and Manufacturing Plants Analysis of Amifostine
4 Global Amifostine Overall Market Overview
5 Amifostine Regional Market Analysis
6 Global 2013-2018E Amifostine Segment Market Analysis (by Type)
7 Global 2013-2018E Amifostine Segment Market Analysis (by Application)
8 Major Manufacturers Analysis of Amifostine
9 Development Trend of Analysis of Amifostine Market
10 Amifostine Marketing Type Analysis
11 Consumers Analysis of Amifostine
12 Conclusion of the Global Amifostine Market Professional Survey Report 2017
Inquire more about this report at: https://www.themarketreports.com/report/ask-your-query/976410
The Market Reports
We aim to provide the best industry and market research report to a seeker. Today, ‘The Market Reports’ is a one stop destination for all the report buyers. We have a collection of over 700,000+ research, company, market, SWOT, trends and analysis reports of various countries, categories and domain to meet an organization need.
Website: https://www.themarketreports.com/
Write us at sales@themarketreports.com
Contact Information:
The Market Reports
Shirish Gupta
Tel: +1-631-407-1315
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
The Market Reports
Shirish Gupta
Tel: +1-631-407-1315
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results